Romain Guery

Romain Guery

Auto-generated profile, based on publicly available information

Romain Guery

Department of Internal Medicine and Infectious Diseases, Hôpital du Confluent, Nantes, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2018 in Science Immunology
Verified
Journal Article
Closed access
PDF file
Vivien BéziatVivien Béziat
Vivien Béziat
JLJuan Li
Juan Li
JLJian-Xin Lin
Jian-Xin Lin
CMCindy S. Ma
Cindy S. Ma
PLPeng Li
Peng Li
JCJean-Laurent Casanova
Jean-Laurent Casanova
ZNF341 is a newly characterized transcription factor controlling baseline and inducible transcription of the human STAT3 gene.

20 November 2017 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
RGRomain Guery
Romain Guery
BHBenoit Henry
Benoit Henry
GMGuillaume Martin-Blondel
Guillaume Martin-Blondel
CRClaire Rouzaud
Claire Rouzaud
FCFlorence Cordoliani
Florence Cordoliani
TNthe French Cutaneous Leishmaniasis Study group & the LeishMan network
the French Cutaneous Leishmaniasis Study group & the LeishMan network
Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Liposomal amphotericin B (L-AmB) has a strong potential for a solid clinical benefit in this indication. We conducted a retrospective analysis of data from a French centralized referral treatment program and from the “LeishMan” European consortium database. All patients with parasitologically proven CL or MCL who received at least one dose of L-AmB were included. Positive outcome was based on ulcer closure as per recent WHO workshop guidelines. From 2008 through 2016, 43 travelers returning from 18 countries (Old World n = 28; New World n = 15) were analyzed with a median follow-up duration of 79 days [range 28–803]. Main clinical forms were: localized CL with one or multiple lesions (n = 32; 74%) and MCL (n = 8; 19%). As per published criteria 19 of 41 patients (46%) were cured 90 days after one course of L-AmB. When the following items -improvement before day 90 but no subsequent follow-up, delayed healing (>3 months) and healing after a second course of L-AmB- were included in the definition of cure, 27 of 43 patients (63%) had a positive outcome. Five patients (MCL = 1; CL = 4) experienced a relapse after a median duration of 6 months [range 3–27] post treatment and 53% of patients (23/43) experienced at least one adverse event including severe hypokalaemia and acute cardiac failure (one patient each). In multivariate analysis, tegumentary infection with L. infantum was associated with complete healing after L-AmB therapy (OR 5.8 IC 95% [1.03–32]) while infection with other species had no impact on outcome. In conditions close to current medical practice, the therapeutic window of L-AmB was narrow in travellers with CL or MCL, with the possible exception of those infected with L. infantum. Strict follow-up is warranted when using L-AmB in patients with mild disease. Cutaneous and muco-cutaneous leishmaniasis (CL/MCL) are disfiguring diseases caused by a worldwide distributed parasite called Leishmania and its 20 species. Clinical manifestations span a wide continuum from single nodular lesion to disseminated form with mucosal involvement. Though local treatment with cryotherapy and intralesionnal antimony or topical formulations of paromomycin is generally adequate in most of situations, some patients with complex CL/MCL require systemic therapy. No convenient regimen has been proved to be safe and effective for all infecting species, all clinical forms and all patients (e.g. children, pregnant women, adults with comorbidities or immunosuppression). In this study, the authors examined in returning travelers with CL/MCL the effectiveness of an antifungal agent “liposomal amphotericin B” (L-AmB), which is highly effective in visceral leishmaniasis. Surprisingly, rates of healing were lower than in previous reports in this unselected population that reflects clinical practice in non-endemic countries. The observations also suggest that some Leishmania species (namely, L. infantum) may be more susceptible to L-AmB than others. Occurrence of adverse events should raises the question of the benefit-risk balance of L-AmB in CL/MCL. Careful attention to comorbidities and adoption of strict protocols for administration are pre-requisites for the use of L-AmB in patients with CL/MCL.

17 December 2018 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
SDSarah Dellière
Sarah Dellière
RGRomain Guery
Romain Guery
SCSophie Candon
Sophie Candon
BRBlandine Rammaert
Blandine Rammaert
CAClaire Aguilar
Claire Aguilar
Olivier LortholaryOlivier Lortholary
Olivier Lortholary
Immune deficiency of diverse etiology, including human immunodeficiency virus (HIV), antineoplastic agents, immunosuppressive agents used in solid organ recipients, immunomodulatory therapy, and other biologics, all promote invasive fungal infections. Subsequent voluntary or unintended immune recovery may induce an exaggerated inflammatory response defining immune reconstitution inflammatory syndrome (IRIS), which causes significant mortality and morbidity. Fungal-associated IRIS raises several diagnostic and management issues. Mostly studied with Cryptococcus, it has also been described with other major fungi implicated in human invasive fungal infections, such as Pneumocystis, Aspergillus, Candida, and Histoplasma. Furthermore, the understanding of IRIS pathogenesis remains in its infancy. This review summarizes current knowledge regarding the clinical characteristics of IRIS depending on fungal species and existing strategies to predict, prevent, and treat IRIS in this patient population, and tries to propose a common immunological background to fungal IRIS.

13 October 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
RGRomain Guery
Romain Guery
SWStephen L. Walker
Stephen L. Walker
GHGundel Harms
Gundel Harms
Andreas NeumayrAndreas Neumayr
Andreas Neumayr
PTPieter Van Thiel
Pieter Van Thiel
OGon behalf of the LeishMan Network and the French Cutaneous Leishmaniasis Study group
on behalf of the LeishMan Network and the French Cutaneous Leishmaniasis Study group
Background: Cutaneous leishmaniasis (CL) is frequent in travellers and can involve oro-nasal mucosae. Clinical presentation impacts therapeutic management. Methodology: Demographic and clinical data from 459 travellers infected in 47 different countries were collected by members of the European LeishMan consortium. The infecting Leishmania species was identified in 198 patients. Principal findings: Compared to Old World CL, New World CL was more frequently ulcerative (75% vs 47%), larger (3 vs 2cm), less frequently facial (17% vs 38%) and less frequently associated with mucosal involvement (2.7% vs 5.3%). Patients with mucosal lesions were older (58 vs 30 years) and more frequently immunocompromised (37% vs 3.5%) compared to patients with only skin lesions. Young adults infected in Latin America with L. braziliensis or L. guyanensis complex typically had an ulcer of the lower limbs with mucosal involvement in 5.8% of cases. Typically, infections with L. major and L. tropica acquired in Africa or the Middle East were not associated with mucosal lesions, while infections with L. infantum, acquired in Southern Europe resulted in slowly evolving facial lesions with mucosal involvement in 22% of cases. Local or systemic treatments were used in patients with different clinical presentations but resulted in similarly high cure rates (89% vs 86%). Conclusion/Significance: CL acquired in L. infantum-endemic European and Mediterranean areas displays unexpected high rates of mucosal involvement comparable to those of CL acquired in Latin America, especially in immunocompromised patients. When used as per recommendations, local therapy is associated with high cure rates.

1 November 2020 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
RGR. Guery
R. Guery
CDC. Delaye
C. Delaye
NBN. Brule
N. Brule
VNV. Nael
V. Nael
LCL. Castain
L. Castain
LDL. De Decker
L. De Decker

1 June 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
APA. Pouvaret
A. Pouvaret
RGR. Guery
R. Guery
MMM. Montillet
M. Montillet
TMT.J. Molina
T.J. Molina
ADA. Duréault
A. Duréault
OLO. Lortholary
O. Lortholary